FDA muddies water for Lundbeck/Otsuka's depot aripiprazole
06:35 EDT 30 Jul 2012 | SCRIP
The US FDA has issued a complete response letter to Lundbeck and Otsuka Pharmaceutical for their new drug application (NDA) for an intramuscular depot formulation of aripiprazole (Abilify), for the maintenance treatment of adult patients with.....
Original Article: FDA muddies water for Lundbeck/Otsuka's depot aripiprazole
More From BioPortfolio on "FDA muddies water for Lundbeck/Otsuka's depot aripiprazole"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
